公开(公告)号：US20240327476A1

公开(公告)日：2024-10-03

申请号：US18634220

申请日：2024-04-12

申请人： ModernaTx, Inc.

发明人： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC分类号： C07K14/47 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/50 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K38/45 ,  A61K38/48 ,  A61K39/395 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K48/00 ,  C07K14/005 ,  C07K14/435 ,  C07K14/475 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  C07K19/00 ,  C12N9/00 ,  C12N9/02 ,  C12N9/10 ,  C12N9/16 ,  C12N9/24 ,  C12N9/42 ,  C12N9/64 ,  C12N9/88 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00

CPC分类号： C07K14/47 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K9/14 ,  A61K9/145 ,  A61K9/5031 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/1767 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/215 ,  A61K38/36 ,  A61K38/363 ,  A61K38/44 ,  A61K38/45 ,  A61K38/4833 ,  A61K38/4846 ,  A61K39/3955 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0066 ,  A61K48/0075 ,  C07K14/005 ,  C07K14/435 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/2887 ,  C07K16/32 ,  C07K19/00 ,  C12N9/0069 ,  C12N9/1051 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/644 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y304/21005 ,  C12Y603/02019 ,  A61K9/0019 ,  A61K38/00 ,  A61K48/00 ,  C07K14/475 ,  C12N2840/00 ,  C12N2840/85 ,  C12Y304/21022

摘要： The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US12076438B2

公开(公告)日：2024-09-03

申请号：US17066919

申请日：2020-10-09

申请人： Translate Bio, Inc.

发明人： Christian Cobaugh ,  Richard Wooster ,  Frank DeRosa ,  Anusha Dias ,  Shrirang Karve

IPC分类号： A61K9/127 ,  A61K9/00 ,  A61K38/17 ,  A61K38/19 ,  A61K38/20 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K9/127 ,  A61K9/0019 ,  A61K9/007 ,  A61K9/0078 ,  A61K38/1709 ,  A61K38/19 ,  A61K38/193 ,  A61K38/208 ,  A61K45/06 ,  A61P35/00

摘要： The present invention provides, among other things, methods and compositions for cancer treatment. The methods and compositions disclosed herein are particularly effective in reducing the size/volume of a tumor and inhibiting tumor growth.

公开(公告)号：US12048687B2

公开(公告)日：2024-07-30

申请号：US17166568

申请日：2021-02-03

申请人： MedRegen, LLC

发明人： Zhaoli Sun ,  George Melville Williams ,  Qing Lin

IPC分类号： A61K31/395 ,  A61K31/436 ,  A61K31/4427 ,  A61K31/5377 ,  A61K38/13 ,  A61K38/18 ,  A61K38/19 ,  A61K45/06 ,  A61P17/02

CPC分类号： A61K31/395 ,  A61K31/436 ,  A61K31/4427 ,  A61K31/5377 ,  A61K38/13 ,  A61K38/18 ,  A61K38/193 ,  A61K45/06 ,  A61P17/02 ,  A61K31/395 ,  A61K2300/00 ,  A61K31/4427 ,  A61K2300/00 ,  A61K31/436 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K38/193 ,  A61K2300/00 ,  A61K38/13 ,  A61K2300/00 ,  A61K38/18 ,  A61K2300/00

摘要： The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization. In one embodiment, a method for improving wound healing in a patient comprises administering to the patient a therapeutically effective amount of a stem cell mobilizer and a low dose of an immunosuppressive agent.

公开(公告)号：US20240245752A1

公开(公告)日：2024-07-25

申请号：US16538853

申请日：2019-08-13

申请人： TIANJIN PEGYLATT BIOTECHNOLOGY CO., LTD

发明人： Xuan Zhang

IPC分类号： A61K38/19 ,  A61K9/00 ,  A61K38/38 ,  A61K47/60 ,  A61P7/00

CPC分类号： A61K38/193 ,  A61K9/0019 ,  A61K38/38 ,  A61K47/60 ,  A61P7/00

摘要： The present invention provides a method to treat and/or prevent febrile neutropenia and Grade 3/4 neutropenia. The method comprises application a Declined mobilizing granulocyte colony-stimulating factor (De-mobilized G-CSF) at a selected time, and a controlled dosage depended on the severity of neutropenia. The present invention also provides evidences to identify the De-mobilized G-CSF and High-mobilized G-CSF, and a method for preparing the De-mobilized G-CSF.

公开(公告)号：US20240230683A1

公开(公告)日：2024-07-11

申请号：US18560365

申请日：2022-05-13

申请人： Board of Regents of the University Of Nebraska

发明人： Howard GENDELMAN ,  R. Lee MOSLEY ,  Mai MOSTAFA ,  Katherine OLSON

IPC分类号： G01N33/68 ,  A61K31/198 ,  A61K38/17 ,  A61K38/19 ,  A61K38/22 ,  A61P25/16

CPC分类号： G01N33/6896 ,  A61K31/198 ,  A61K38/1709 ,  A61K38/193 ,  A61K38/2278 ,  A61P25/16 ,  G01N2333/4703 ,  G01N2333/916 ,  G01N2800/2835 ,  G01N2800/52

摘要： Provided are methods for monitoring the progression of Parkinson's Disease, and methods for monitoring or determining the effectiveness of therapeutics for the treatment of Parkinson's Disease, as well as methods for treatment thereof, by assessing one or more biomarkers, such as NF-κB and/or calcineurin.

公开(公告)号：US20240165267A1

公开(公告)日：2024-05-23

申请号：US18058656

申请日：2022-11-23

申请人： ModernaTX, Inc.

发明人： Atanu ROY ,  Christopher R. CONLEE ,  Antonin DE FOUGEROLLES ,  Andrew W. FRALEY

IPC分类号： A61K48/00 ,  A61K38/18 ,  A61K38/19 ,  C07H19/10 ,  C07H21/00 ,  C12N15/11 ,  C12P19/34 ,  C12P21/00

CPC分类号： A61K48/0066 ,  A61K38/1816 ,  A61K38/193 ,  C07H19/10 ,  C07H21/00 ,  C12N15/11 ,  C12P19/34 ,  C12P21/00 ,  C12P21/005 ,  A61K48/00 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/335 ,  C12N2310/336 ,  C12N2320/30

摘要： The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

公开(公告)号：US20240123035A1

公开(公告)日：2024-04-18

申请号：US18177455

申请日：2023-03-02

申请人： ModernaTX, Inc.

发明人： Antonin DE FOUGEROLLES ,  Kristy M. Wood ,  Sayda M. ELBASHIR ,  Noubar B. Afeyan ,  Pedro VALENCIA ,  Jason P. SCHRUM

IPC分类号： A61K38/19 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/16 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/48 ,  A61K48/00 ,  C07K2/00 ,  C07K14/535 ,  C12N15/00 ,  C12N15/117 ,  C12N15/88 ,  C12P21/00

CPC分类号： A61K38/193 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0048 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/14 ,  A61K9/16 ,  A61K9/1647 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/4833 ,  A61K48/00 ,  A61K48/0033 ,  A61K48/0041 ,  A61K48/005 ,  A61K48/0066 ,  C07K2/00 ,  C07K14/535 ,  C12N15/00 ,  C12N15/117 ,  C12N15/88 ,  C12P21/00

摘要： The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

公开(公告)号：US11951133B2

公开(公告)日：2024-04-09

申请号：US17864307

申请日：2022-07-13

申请人： Nurix Therapeutics, Inc.

发明人： Arthur T. Sands ,  Neil F. Bence ,  Christoph W. Zapf ,  Frederick Cohen ,  Chenbo Wang ,  Thomas Cummins ,  Hiroko Tanaka ,  Hunter Shunatona ,  Mario Cardozo ,  Dahlia Weiss ,  Jennifa Gosling

IPC分类号： A61K35/17 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4545 ,  A61K33/243 ,  A61K35/761 ,  A61K35/763 ,  A61K35/768 ,  A61K38/19 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/107 ,  C07F5/02 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4545 ,  A61K33/243 ,  A61K35/761 ,  A61K35/763 ,  A61K35/768 ,  A61K38/193 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/3955 ,  A61K45/06 ,  A61N5/1001 ,  A61N5/1077 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/107 ,  C07F5/022 ,  C12N5/0636 ,  A61K2039/5152 ,  C12N2501/2302 ,  C12N2501/998 ,  C12N2501/999

摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

公开(公告)号：US20240108622A1

公开(公告)日：2024-04-04

申请号：US18377561

申请日：2023-10-06

申请人： Aerovate Therapeutics, Inc.

发明人： Ben Dake ,  Ralph Niven ,  Andrew D. Levin

IPC分类号： A61K31/506 ,  A61K9/00 ,  A61K31/501 ,  A61K38/18 ,  A61K38/19 ,  A61K47/26 ,  A61P9/12 ,  A61P11/00

CPC分类号： A61K31/506 ,  A61K9/0073 ,  A61K9/0075 ,  A61K9/0078 ,  A61K31/501 ,  A61K38/1858 ,  A61K38/193 ,  A61K47/26 ,  A61P9/12 ,  A61P11/00 ,  C07B2200/13

摘要： The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.

公开(公告)号：US20240066126A1

公开(公告)日：2024-02-29

申请号：US18455544

申请日：2023-08-24

申请人： Regen Biopharma, Inc.

发明人： Thomas ICHIM ,  David KOOS ,  Harry LANDER

IPC分类号： A61K39/00 ,  A61K38/17 ,  A61K38/19

CPC分类号： A61K39/4631 ,  A61K38/1725 ,  A61K38/193 ,  A61K39/4614

摘要： Disclosed are combination therapies for cancer utilizing the leverage of the adaptive immune system through chimeric antigen receptor (CAR) T cells, combined with leveraging the innate immune system by using CAR-macrophages (CAR-M) and CAR-natural killer (NK) cells. In some embodiments, the invention teaches the initial modification of the tumor microenvironment by administration of CAR-M and CAR-NK. The alteration of the tumor microenvironment results in reduction of barriers for CAR-T cells to enter the tumor, which allows for efficacy of CAR-T in treatment of solid tumors. In some embodiments adjuvant immunotherapies are utilized to expand immunological attack such as addition of complement, immunotherapeutic antibodies, chemotherapy and radiotherapy approaches.